Hot Flashes and Night Sweats During Perimenopause: What's Happening and What Helps

DEFINITION

Vasomotor symptoms

The clinical term for hot flashes and night sweats during perimenopause and menopause. Caused by the hypothalamus — which regulates body temperature — becoming hypersensitive to small changes in core temperature as estrogen levels decline.

DEFINITION

Thermoregulatory dysfunction

The mechanism underlying vasomotor symptoms. Declining estrogen narrows the thermoneutral zone — the temperature range within which the body makes no attempt to cool or warm itself. Minor temperature fluctuations that would previously go unnoticed now trigger a heat-dissipation response: flushing, sweating, rapid heart rate.

What Is Happening During a Hot Flash

A hot flash is a sudden wave of heat — typically felt in the upper body, face, and neck — accompanied by skin flushing, sweating, and often a rapid heartbeat. The episode usually lasts 1-5 minutes and may be followed by chills. Night sweats are the nocturnal equivalent: the same physiological event occurring during sleep.

The mechanism is thermoregulatory. Estrogen normally maintains the hypothalamic thermostat within a broad comfortable range. As estrogen declines, this range narrows. Minor core temperature increases — from a warm room, a glass of wine, or simply lying under a duvet — trigger a heat-dissipation response disproportionate to the stimulus.

Prevalence and Duration

Vasomotor symptoms affect approximately 75-80% of perimenopausal women. Severity varies significantly. For some women, hot flashes are mild and occasional; for others, they occur multiple times per hour and significantly disrupt daily function and sleep.

The SWAN study found that median duration of bothersome vasomotor symptoms was approximately 7 years — beginning in perimenopause and often continuing into the post-menopausal years. Women who begin experiencing hot flashes earlier in the perimenopause transition tend to have a longer symptom duration.

Treatment Options

HRT remains the gold standard. Estrogen therapy reduces hot flash frequency by 75-90% in clinical trials. It is available in multiple formulations — patches, gels, sprays, pills — with different risk profiles. Progestogen is added for women with a uterus.

Non-hormonal options include SSRIs/SNRIs (paroxetine, venlafaxine), which reduce frequency by 50-60%; gabapentin; and fezolinetant, a neurokinin 3 receptor antagonist that specifically targets the hypothalamic pathway driving hot flashes.

Lifestyle modifications — avoiding identified triggers, keeping sleeping environments cool, wearing breathable fabrics — can reduce frequency and severity for some women, though evidence is weaker than for pharmacological options.